Clobetasol
| Evidence Level: L3 | Predicted Indications: 1 |
Table of Contents
Clobetasol: From Inflammatory Dermatoses to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Clobetasol is a super-potent (class IV) topical corticosteroid conventionally used for inflammatory and pruritic dermatoses. The TxGNN model predicts it may be effective for Primary Cutaneous T-Cell Lymphoma (CTCL), with 0 registered clinical trials but 20 supporting publications, including a cohort study and a direct comparative efficacy study, currently backing this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record in this jurisdiction (drug is not locally marketed; no approved-label indication text available) |
| Predicted New Indication | Primary Cutaneous T-Cell Lymphoma |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L3 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for Clobetasol is not available from DrugBank in this evidence pack (flagged as a High-severity data gap). Based on established pharmacology, Clobetasol propionate is a superpotent (class IV) topical corticosteroid known to suppress local inflammation and T-cell–mediated immune responses — it inhibits cytokine release and induces apoptosis of infiltrating lymphocytes. This mechanism gives it a direct, plausible effect on the malignant T-cell infiltrates that characterize cutaneous T-cell lymphoma (CTCL), particularly early-stage (patch-stage) mycosis fungoides.
The relationship between Clobetasol’s conventional use in inflammatory/pruritic skin disease and the predicted new indication is mechanistically close: both settings involve pathological T-cell activity within the skin, and topical corticosteroids are already recognized in clinical practice (e.g., NCCN guidance, and the classic Zackheim case series below) as a standard first-line option for early-stage CTCL. This lends strong mechanistic plausibility to the TxGNN prediction.
That said, the supporting evidence is concentrated in early/patch-stage mycosis fungoides. Evidence for advanced tumor-stage disease or other CTCL subtypes (e.g., Sézary syndrome) is not established, and the prediction should not be extrapolated beyond early-stage disease without further data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32603400 | 2020 | Cohort | Cutis | Observational study of topical clobetasol propionate 0.05% cream in early-stage mycosis fungoides; confirmed efficacy of superpotent topical corticosteroids with manageable cutaneous adverse effects |
| 39741016 | 2025 | Comparative study | Anais Brasileiros de Dermatologia | Compared efficacy of clobetasol propionate versus bexarotene in early-stage mycosis fungoides |
| 14686970 | 2003 | Case series | Dermatologic Therapy | ~200 patients with patch-stage mycosis fungoides treated with high-potency topical corticosteroids (predominantly clobetasol) at UCSF; response rate >90% with minor side effects; established topical clobetasol as first-line treatment for early-stage MF |
| 30677799 | 2018 | Review | Dermatology Online Journal | Review of lymphomatoid papulosis, a CD30+ lymphoproliferative disorder within the CTCL spectrum, with excellent long-term prognosis |
| 17083888 | 2006 | Review | Dermatology Online Journal | Review of CD30+ large T-cell lymphoma diagnostic distinction and management within the CTCL spectrum |
| 25027222 | 2014 | Case Report | Nederlands Tijdschrift voor Geneeskunde | 9-year-old girl with hypopigmented mycosis fungoides successfully treated with clobetasol 0.05% ointment, 4 days/week |
| 28031140 | 2016 | Case Report | Skinmed | Patient with cutaneous angioimmunoblastic T-cell lymphoma initially treated with topical clobetasol before diagnosis was established |
| 36846176 | 2023 | Case Report | Clinical Case Reports | Mycosis fungoides presenting with psoriasiform plaques; initially managed with topical corticosteroids; includes literature review |
| 28804923 | 2017 | Case Report | Pediatric Dermatology | Hypopigmented mycosis fungoides with large-cell transformation in an 8-year-old child |
| 23773745 | 2013 | Case Report | Annales de Dermatologie et de Venereologie | Case report and literature review of papular mycosis fungoides, an early incipient form of the disease |
Safety Considerations
Drug Interactions: A DDI screen (source: DDInter) identified 175 potential interacting drugs; interaction severity levels are not yet classified (all recorded as “Unknown” in the current dataset). Notable interacting agents include other systemic/topical corticosteroids (Prednisone, Prednisolone, Hydrocortisone, Triamcinolone) — combined use may raise the risk of additive immunosuppression or HPA-axis suppression — and Vitamin A / Calcitriol, relevant if co-administered with other topical vitamin A or D analogues in dermatologic regimens.
Detailed prescribing warnings and contraindications for Clobetasol are not yet available in this evidence pack — this is flagged as a Blocking data gap that must be resolved before a formal safety pre-assessment (S1) can proceed (see Conclusion below).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is strong and is reinforced by a cohort study, a direct clobetasol-vs-bexarotene comparative study, and a well-established historical case series (>200 patients, >90% response) supporting topical clobetasol as first-line therapy in early-stage mycosis fungoides — consistent with the L3 evidence level and TxGNN’s high prediction score (99.51%). However, no clinical trials are registered for this specific indication, the drug is not currently marketed in this jurisdiction, and key local safety documentation (TFDA warnings/contraindications) is missing, warranting a guarded rather than unconditional recommendation.
To proceed, the following is needed:
- TFDA-approved product label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action (MOA) data from DrugBank — currently a High-severity data gap (DG002)
- Clarification of local market/import pathway, since the drug currently holds no local registrations
- Scoping of any future trial or protocol strictly to early-stage/patch-stage CTCL, given the lack of evidence for advanced-stage or other CTCL subtypes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.